Compare Cytokinetics Inc (CYTK) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Toronto-Dominion Bank — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Toronto-Dominion Bank trades at $121.35 (market cap $199.91B). The key difference: Toronto-Dominion Bank is far larger — about 18.5× Cytokinetics Inc's market cap, and Toronto-Dominion Bank pays a 2.64% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | TD | |
|---|---|---|
Market Cap | $10.78B | $199.91B |
Sector | Technology | Financials |
52-Week High | $87.26 | $124.80 |
52-Week Low | $34.31 | $72.85 |
Enterprise Value | $10.88B | — |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
TD stock trades at $121.31, up 0.11% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.74, exceeding the $1.63 estimate, and maintains a strong net income margin of 23.38%. Analyst consensus is positive with 9 buy ratings and no sell ratings among 17 analysts. Recent news highlights value comparisons with peers and dividend stability.
Outlook remains favorable due to consistent earnings performance and robust profitability, though risks include high debt levels and potential regulatory scrutiny. The stock's valuation at a P/E of 19.95 is reasonable relative to historical margins, supporting a cautious bullish view for long-term investors seeking dividend income and steady growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
